This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PRESENTATION ON NW BIO'S DCVAX-DIRECT TRIAL ANNOUNCED FOR ASCO ANNUAL MEETING

BETHESDA, Md., April 22, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that ASCO (the American Society for Clinical Oncology) has announced in its Annual Meeting program that the Company will present its DCVax-Direct clinical trial and technology in a general poster session at this year's ASCO meeting, taking place in Chicago May 30 through June 3.  The abstract is number TPS3133, and the poster is number 189(a).
Northwest Biotherapeutics Logo

ASCO is the largest and most important annual conference on cancer treatments, with some 30,000 oncologists and other medical personnel, analysts and others attending from all over the world.  Last year, immune therapy emerged as the top new focus area.  This year, the focus on immune therapies like DCVax is expected to be even greater. 

ASCO's acceptance of the abstract about the Company's DCVax-Direct technology and its large Phase I/II trial provides an opportunity for leading oncologists, analysts, investors and media to learn more about the unique DCVax-Direct program, now in trials on a range of multiple inoperable cancers.  The abstract will be presented in a general poster session.

The Company will also have a large exhibit booth in the ASCO exhibit hall, where further information will be provided about the Company's DCVax technology.  Its DCVax-L and DCVax-Direct clinical trial programs provide a series of customized vaccine injections which educate a patient's immune system to attack that individual's specific cancer without any toxic side effects.  In clinical trials to date on a variety of solid tumor cancers, the results have been encouraging.

DCVax-Direct specifically is a personalized immune therapy for inoperable solid tumors, using dendritic cells (the master cells of the immune system) to mobilize the immune system to attack the patient's cancer.  DCVax-Direct is administered by direct injection into the patient's tumors.  It can be injected into any number of tumors, enabling patients with locally advanced disease or with metastases to be treated.  DCVax-Direct can also be injected into tumors in virtually any location in the body (with ultra-sound guidance for interior locations).  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs